biostudies-literatureUnknown43(3)Findlay JUniversity of Fribourg<h4>Objectives</h4>The occurrence of metallo-beta-lactamase-producing Pseudomonas aeruginosa (MBL-PA) isolates is increasing globally, including in Switzerland. The aim of this study was to characterise, phenotypically and genotypically, the MBL-PA isolates submitted to the Swiss National Reference Center for Emerging Antibiotic Resistance (NARA) reference laboratory over a 12-month period from July 2022 to July 2023.<h4>Methods</h4>Thirty-nine non-duplicate MBL-PA Isolates were submitted to NARA over the study period from across Switzerland. Susceptibility was determined by broth microdilution according to EUCAST methodology. Whole-genome sequencing was performed on 34 isolates. Sequence types (STs) and resistance genes were ascertained using the Centre for Genomic Epidemiology platform. MBL genes, bla_NDM-1, bla_IMP-1, and bla_VIM-2, were cloned into vector pUCP24 and transformed into P. aeruginosa PA14.<h4>Results</h4>The most prevalent MBL types identified in this study were VIM (21/39; 53.8%) followed by NDM (11/39; 28.2%), IMP (6/39; 15.4%), and a single isolate produced both VIM and NDM enzymes. WGS identified 13 different STs types among the 39 isolates. They all exhibited resistance to cephalosporins, carbapenems, and the beta-lactam-beta-lactamase inhibitor combinations, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam, and 8 isolates were cefiderocol (FDC) resistant. Recombinant P. aeruginosa strains producing bla_NDM-1, bla_IMP-1, and bla_VIM-2 exhibited FDC MICs of 16, 8, and 1 mg/L, respectively.<h4>Conclusions</h4>This study showed that the MBL-PA in Switzerland could be attributed to the wide dissemination of high-risk clones that accounted for most isolates in this study. Although FDC resistance was only found in 8 isolates, MBL carriage was shown to be a major contributor to this phenotype.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology551-557https://www.ebi.ac.uk/biostudies/studies/S-EPMC10917820biostudies-literatureMolecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022-2023.PMC10917820Lemaire BMonnerat LBBoschung DFankhauser HGreub GDubois OMoraz MPranghofer SCasanova CElzi MPfister SGuler CMenozzi FBGoldenberger DEmonet SHitz ENarr KPozzi LLiassine NMathis BRaro OHFBandeira DCirillo CSuterbuser BStaehli PKeller PJayol ASchmid SSchultze DOberle MScherler AHerzog KMitrovic IVonallmen LSchmid TWohlwend NGraf SBurren KLienhard RPayen CNARA NetworkImhof AJutzi MFournier CPoirel LDubey NVitale AMaitrejean MFindlay JFricker CBlanc DMaret RKuegler MMarti COSchoenenberger MLucke KRumebe LBasilico LSchoch SDroz SHyden DLang CSchnell BSchibli UBorn YAndreutti CTogni GImperiali MPiran FBruderer VWesters AZowa CBelo AGruner EFatoux MGuyon CJost GVaninetti GSeiffert SBalzari DCastelberg CEgli AGisler VSteffen IPianezzi EDeggi-Messmer VAndrey DTritten MPovolo VEllenberger SRenzi GNusbaumer CBrandenberger MZehnder CLucchini GMCherkaoui ASchrenzel JDilorenzo VNordmann PPreiswerk BComte LSchilt CIvan BKarrer UDessauges MMancini SBlaich AReichmuth MGaia VMabillard DEyer MMinkova PSchacher MfalseMolecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022-2023.<h4>Objectives</h4>The occurrence of metallo-beta-lactamase-producing Pseudomonas aeruginosa (MBL-PA) isolates is increasing globally, including in Switzerland. The aim of this study was to characterise, phenotypically and genotypically, the MBL-PA isolates submitted to the Swiss National Reference Center for Emerging Antibiotic Resistance (NARA) reference laboratory over a 12-month period from July 2022 to July 2023.<h4>Methods</h4>Thirty-nine non-duplicate MBL-PA Isolates were submitted to NARA over the study period from across Switzerland. Susceptibility was determined by broth microdilution according to EUCAST methodology. Whole-genome sequencing was performed on 34 isolates. Sequence types (STs) and resistance genes were ascertained using the Centre for Genomic Epidemiology platform. MBL genes, bla_NDM-1, bla_IMP-1, and bla_VIM-2, were cloned into vector pUCP24 and transformed into P. aeruginosa PA14.<h4>Results</h4>The most prevalent MBL types identified in this study were VIM (21/39; 53.8%) followed by NDM (11/39; 28.2%), IMP (6/39; 15.4%), and a single isolate produced both VIM and NDM enzymes. WGS identified 13 different STs types among the 39 isolates. They all exhibited resistance to cephalosporins, carbapenems, and the beta-lactam-beta-lactamase inhibitor combinations, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam, and 8 isolates were cefiderocol (FDC) resistant. Recombinant P. aeruginosa strains producing bla_NDM-1, bla_IMP-1, and bla_VIM-2 exhibited FDC MICs of 16, 8, and 1 mg/L, respectively.<h4>Conclusions</h4>This study showed that the MBL-PA in Switzerland could be attributed to the wide dissemination of high-risk clones that accounted for most isolates in this study. Although FDC resistance was only found in 8 isolates, MBL carriage was shown to be a major contributor to this phenotype.2024-01-01T00:00:00Z2024 Mar2026-06-09T07:09:04.161Z2025-04-07T02:10:05.692ZS-EPMC109178203823361010.1007/s10096-024-04752-8